Real-world Evidence Non-Interventional proSpective Study of kisqaLi (Ribociclib) Effectiveness and safEty in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Ribociclib (Primary)
- Indications Breast cancer; HER2 negative breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 03 Feb 2025 New trial record